Cleveland, OHNCT02982902Now EnrollingIRB Ready

Cytomegalovirus Infections Clinical Trial in Cleveland, OH

Access cutting-edge cytomegalovirus infections treatment through this early phase 1 clinical trial at a research site in Cleveland. Study-provided care at no cost to qualified participants.

Sponsored by Mari Dallas

Quick Self-Assessment

See if you qualify for this Cleveland location

Preparing your pre-screening questions…

Expert Care in Cleveland

Access cytomegalovirus infections specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cytomegalovirus infections treatment provided free

Apply for This Cleveland Location

Check if you qualify for this cytomegalovirus infections clinical trial in Cleveland, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Cleveland

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Cleveland site if eligible
  4. 4Begin participation

About This Cytomegalovirus Infections Study in Cleveland

The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus (CMV) is feasible to treat infections by CMV. Adoptive T-cell therapy is an investigational (experimental) therapy that works by using the blood of a donor and selecting the T-cells that can respond against a specific infectious entity. These selected T-cells are then infused to the patient, to try to give the immune system the ability to fight the infection. Adoptive T-cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).

Sponsor: Mari Dallas

Who Can Participate

Inclusion Criteria

Patients must have received allogeneic hematopoietic stem cell transplant and be greater than 30 days post-transplant at the time of registration
Patients must have documented opportunistic CMV infection, or reactivation; the criteria include (both of the following criteria must be met)
Patients may have asymptomatic viremia (\>1000 copies/ml) OR presence of symptoms secondary to CMV infection, AND
Patients must have ONE OF THE NEXT FOUR CRITERIA:
Absence of an improvement of viral load after ≥ 14 days of antiviral therapy with ganciclovir, valganciclovir or foscarnet (decrease by at least 1 log, i.e. 10-fold) or
New, persistent and/or worsening CMV-related symptoms, signs and/or markers of end organ compromise while on antiviral therapy with ganciclovir, valganciclovir or foscarnet, or
Have contraindications or experience adverse effects of antiviral therapy with ganciclovir, valganciclovir or foscarnet.
Second recurrence of CMV viremia, CMV-related symptoms, signs and/or markers of end organ compromise.
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3
Women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) 4 weeks prior to study entry, for the duration of study participation and for 3 months after completing treatment.
Subjects must have the ability to understand and the willingness to sign a written informed consent document, or assent document.

Exclusion Criteria

Pregnant or breastfeeding women are excluded from this study.
Patients with opportunistic viral infections other than CMV.
Patients with active, grade 2-4, acute graft vs. host disease (GVHD), chronic GVHD or any condition requiring high doses of glucocorticosteroid (\>0.5 mg/kg/day prednisone or its equivalent) as treatment
Treatment with antithymocyte globulin within 28 days of planned infusion of virus - specific, antigen selected T cells.
Treatment with virus - specific T cells within 6 weeks (42 days) of planned infusion. Donor eligibility
Related donor of T cells must be at least partially HLA compatible, matching with recipient in at least 3/6 HLA loci (HLA-A, HLA-B, and HLA-DRB1 loci will be considered for this).
Must have evidence of a serologic response (i.e. be seropositive) against CMV.
Age ≥ 18 years
Must meet the criteria for donor selection defined in the Standard Operating Procedures of University Hospitals Seidman Cancer Center Stem Cell Transplant Program
Must be capable of undergoing a single standard 2 blood volume leukapheresis or donation of one unit of whole blood

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cleveland?

Yes, this clinical trial (NCT02982902) has an active research site in Cleveland, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cytomegalovirus Infections Treatment Options in Cleveland, OH

If you're searching for cytomegalovirus infections treatment options in Cleveland, OH, this clinical trial (NCT02982902) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cleveland research site is actively enrolling participants for this early phase 1 clinical trial. You'll receive care from experienced cytomegalovirus infections specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cytomegalovirus infections clinical trials near you to find additional studies recruiting in your area.

More Geographic Atrophy Trials in Cleveland, OH

See all geographic atrophy clinical trials recruiting in Cleveland — not just this study.

Browse Geographic Atrophy Trials in Cleveland →

Browse More Trials by Condition

Geographic Atrophy TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Cleveland?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Cleveland, OH